IL100904A - Pharmaceuticals containing rapamycin for the treatment of systemic lupus erythematosus - Google Patents

Pharmaceuticals containing rapamycin for the treatment of systemic lupus erythematosus

Info

Publication number: IL100904A
Authority: IL; Israel
Prior art keywords: rapamycin; csa; treated; mrl; sle
Prior art date: 1991-02-22

Application number

IL10090492A

Other languages

English (en)

Hebrew (he)

Other versions

IL100904A0 (en

Original Assignee

American Home Prod

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-02-22

Filing date

1992-02-10

Publication date

1995-10-31

1992-02-10 Application filed by American Home Prod filed Critical American Home Prod

1992-11-15 Publication of IL100904A0 publication Critical patent/IL100904A0/xx

1995-10-31 Publication of IL100904A publication Critical patent/IL100904A/en

Links

ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title claims abstract description 70
229960002930 sirolimus Drugs 0.000 title claims abstract description 70
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title claims abstract description 70
201000000596 systemic lupus erythematosus Diseases 0.000 title claims abstract description 38
239000008194 pharmaceutical composition Substances 0.000 title claims description 10
241000124008 Mammalia Species 0.000 claims abstract description 10
238000000034 method Methods 0.000 claims abstract description 9
238000011161 development Methods 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 6
230000000979 retarding effect Effects 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims 2
238000007911 parenteral administration Methods 0.000 claims 1
229930105110 Cyclosporin A Natural products 0.000 description 45
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 45
108010036949 Cyclosporine Proteins 0.000 description 45
241000699670 Mus sp. Species 0.000 description 39
241000699666 Mus <mouse, genus> Species 0.000 description 21
238000012360 testing method Methods 0.000 description 20
239000003981 vehicle Substances 0.000 description 20
210000004027 cell Anatomy 0.000 description 14
230000000694 effects Effects 0.000 description 13
230000004083 survival effect Effects 0.000 description 12
210000000952 spleen Anatomy 0.000 description 11
108010088751 Albumins Proteins 0.000 description 10
102000009027 Albumins Human genes 0.000 description 10
230000035755 proliferation Effects 0.000 description 10
239000003226 mitogen Substances 0.000 description 9
210000004988 splenocyte Anatomy 0.000 description 9
238000010998 test method Methods 0.000 description 9
108010062580 Concanavalin A Proteins 0.000 description 8
230000004073 interleukin-2 production Effects 0.000 description 8
210000001165 lymph node Anatomy 0.000 description 8
230000004044 response Effects 0.000 description 8
230000002485 urinary effect Effects 0.000 description 8
208000008771 Lymphadenopathy Diseases 0.000 description 7
230000003172 anti-dna Effects 0.000 description 7
230000008859 change Effects 0.000 description 7
230000000144 pharmacologic effect Effects 0.000 description 7
206010018364 Glomerulonephritis Diseases 0.000 description 6
108010002350 Interleukin-2 Proteins 0.000 description 6
102000000588 Interleukin-2 Human genes 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
230000008595 infiltration Effects 0.000 description 6
238000001764 infiltration Methods 0.000 description 6
208000018555 lymphatic system disease Diseases 0.000 description 6
239000002609 medium Substances 0.000 description 6
108010047620 Phytohemagglutinins Proteins 0.000 description 5
230000002962 histologic effect Effects 0.000 description 5
230000001885 phytohemagglutinin Effects 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
238000010171 animal model Methods 0.000 description 4
206010003246 arthritis Diseases 0.000 description 4
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
206010037596 Pyelonephritis Diseases 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
206010062237 Renal impairment Diseases 0.000 description 3
206010041660 Splenomegaly Diseases 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
239000012911 assay medium Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
206010020718 hyperplasia Diseases 0.000 description 3
210000004969 inflammatory cell Anatomy 0.000 description 3
201000006334 interstitial nephritis Diseases 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
201000004537 pyelitis Diseases 0.000 description 3
239000000243 solution Substances 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
210000001541 thymus gland Anatomy 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
208000006820 Arthralgia Diseases 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
206010061818 Disease progression Diseases 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
206010047115 Vasculitis Diseases 0.000 description 2
239000000427 antigen Substances 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
230000003292 diminished effect Effects 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000003907 kidney function Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
210000004789 organ system Anatomy 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
239000008389 polyethoxylated castor oil Substances 0.000 description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
229960004618 prednisone Drugs 0.000 description 2
201000001474 proteinuria Diseases 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
230000004043 responsiveness Effects 0.000 description 2
229940054269 sodium pyruvate Drugs 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
230000002477 vacuolizing effect Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
MRDAXWGGWWDUKL-VKJPNVGWSA-N 3-O-Caffeoylshikimic acid Chemical compound O[C@H]1[C@H](O)CC(C(O)=O)=C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 MRDAXWGGWWDUKL-VKJPNVGWSA-N 0.000 description 1
206010001580 Albuminuria Diseases 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
235000021360 Myristic acid Nutrition 0.000 description 1
108010051791 Nuclear Antigens Proteins 0.000 description 1
102000019040 Nuclear Antigens Human genes 0.000 description 1
206010036141 Polyserositis Diseases 0.000 description 1
206010037855 Rash erythematous Diseases 0.000 description 1
108700005079 Recessive Genes Proteins 0.000 description 1
102000052708 Recessive Genes Human genes 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
241000219061 Rheum Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
210000003797 carpal joint Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000005584 early death Effects 0.000 description 1
208000022532 enlargement of lymph nodes Diseases 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000003304 gavage Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
210000005004 lymphoid follicle Anatomy 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
208000012263 renal involvement Diseases 0.000 description 1
238000011160 research Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
150000005671 trienes Chemical class 0.000 description 1
230000002792 vascular Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Saccharide Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Cephalosporin Compounds (AREA)

IL10090492A 1991-02-22 1992-02-10 Pharmaceuticals containing rapamycin for the treatment of systemic lupus erythematosus IL100904A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/660,470 US5078999A (en)	1991-02-22	1991-02-22	Method of treating systemic lupus erythematosus

Publications (2)

Publication Number	Publication Date
IL100904A0 IL100904A0 (en)	1992-11-15
IL100904A true IL100904A (en)	1995-10-31

Family

ID=24649665

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10090492A IL100904A (en)	1991-02-22	1992-02-10	Pharmaceuticals containing rapamycin for the treatment of systemic lupus erythematosus

Country Status (20)

Country	Link
US (1)	US5078999A (da)
EP (1)	EP0572542B9 (da)
KR (1)	KR100201517B1 (da)
AT (1)	ATE202938T1 (da)
AU (1)	AU664545B2 (da)
CA (1)	CA2103568A1 (da)
CY (1)	CY2305B1 (da)
DE (1)	DE69231927T2 (da)
DK (1)	DK0572542T3 (da)
ES (1)	ES2157901T3 (da)
GR (1)	GR3036477T3 (da)
HU (1)	HUT70489A (da)
IE (1)	IE920556A1 (da)
IL (1)	IL100904A (da)
MX (1)	MX9200727A (da)
NZ (1)	NZ241671A (da)
PT (1)	PT100145B (da)
SG (1)	SG52404A1 (da)
WO (1)	WO1992014477A1 (da)
ZA (1)	ZA921210B (da)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5206018A (en) *	1978-11-03	1993-04-27	Ayerst, Mckenna & Harrison, Inc.	Use of rapamycin in treatment of tumors
US6548640B1 (en) *	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5378696A (en) *	1990-09-19	1995-01-03	American Home Products Corporation	Rapamycin esters
US5221670A (en) *	1990-09-19	1993-06-22	American Home Products Corporation	Rapamycin esters
US5321009A (en) *	1991-04-03	1994-06-14	American Home Products Corporation	Method of treating diabetes
US5194447A (en) *	1992-02-18	1993-03-16	American Home Products Corporation	Sulfonylcarbamates of rapamycin
US5286730A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5286731A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
US5164399A (en) *	1991-11-18	1992-11-17	American Home Products Corporation	Rapamycin pyrazoles
US5516781A (en) *	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
CA2086642C (en) *	1992-01-09	2004-06-15	Randall E. Morris	Method of treating hyperproliferative vascular disease
US5262424A (en) *	1992-02-18	1993-11-16	American Home Products Corporation	Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith
US5177203A (en) *	1992-03-05	1993-01-05	American Home Products Corporation	Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
ATE138807T1 (de)	1992-03-27	1996-06-15	American Home Prod	29-demethoxyrapamycin zur induktion der immunosuppression
US5288711A (en) *	1992-04-28	1994-02-22	American Home Products Corporation	Method of treating hyperproliferative vascular disease
US5256790A (en) *	1992-08-13	1993-10-26	American Home Products Corporation	27-hydroxyrapamycin and derivatives thereof
CA2106034A1 (en) *	1992-09-24	1994-03-25	Ralph J. Russo	21-norrapamycin
US5302584A (en) *	1992-10-13	1994-04-12	American Home Products Corporation	Carbamates of rapamycin
US5480989A (en) *	1992-10-13	1996-01-02	American Home Products Corporation	Carbamates of rapamycin
US5480988A (en) *	1992-10-13	1996-01-02	American Home Products Corporation	Carbamates of rapamycin
US5489680A (en) *	1992-10-13	1996-02-06	American Home Products Corporation	Carbamates of rapamycin
US5434260A (en) *	1992-10-13	1995-07-18	American Home Products Corporation	Carbamates of rapamycin
US5262423A (en) *	1992-10-29	1993-11-16	American Home Products Corporation	Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5260300A (en) *	1992-11-19	1993-11-09	American Home Products Corporation	Rapamycin carbonate esters as immuno-suppressant agents
US5482945A (en) *	1992-12-22	1996-01-09	American Home Products Corporation	Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
US5349060A (en) *	1993-01-07	1994-09-20	American Home Products Corporation	Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5252579A (en) *	1993-02-16	1993-10-12	American Home Products Corporation	Macrocyclic immunomodulators
US5504091A (en) *	1993-04-23	1996-04-02	American Home Products Corporation	Biotin esters of rapamycin
ES2295093T3 (es)	1993-04-23	2008-04-16	Wyeth	Conjugados y anticuerpos de rapamicina.
US7279561B1 (en) *	1993-04-23	2007-10-09	Wyeth	Anti-rapamycin monoclonal antibodies
US5387680A (en) *	1993-08-10	1995-02-07	American Home Products Corporation	C-22 ring stabilized rapamycin derivatives
US5373014A (en) *	1993-10-08	1994-12-13	American Home Products Corporation	Rapamycin oximes
US5391730A (en) *	1993-10-08	1995-02-21	American Home Products Corporation	Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) *	1993-10-08	1995-01-03	American Home Products Corporation	Rapamycin oximes and hydrazones
US5385909A (en) *	1993-11-22	1995-01-31	American Home Products Corporation	Heterocyclic esters of rapamycin
US5385908A (en) *	1993-11-22	1995-01-31	American Home Products Corporation	Hindered esters of rapamycin
US5385910A (en) *	1993-11-22	1995-01-31	American Home Products Corporation	Gem-distributed esters of rapamycin
US5389639A (en) *	1993-12-29	1995-02-14	American Home Products Company	Amino alkanoic esters of rapamycin
US5525610A (en) *	1994-03-31	1996-06-11	American Home Products Corporation	42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5463048A (en) *	1994-06-14	1995-10-31	American Home Products Corporation	Rapamycin amidino carbamates
US5491231A (en) *	1994-11-28	1996-02-13	American Home Products Corporation	Hindered N-oxide esters of rapamycin
US5563145A (en) *	1994-12-07	1996-10-08	American Home Products Corporation	Rapamycin 42-oximes and hydroxylamines
US5561138A (en) *	1994-12-13	1996-10-01	American Home Products Corporation	Method of treating anemia
US5496832A (en) *	1995-03-09	1996-03-05	American Home Products Corporation	Method of treating cardiac inflammatory disease
FR2736550B1 (fr)	1995-07-14	1998-07-24	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
TW427904B (en) *	1995-12-07	2001-04-01	American Home Prod	Neuroprotective agents
US5780462A (en) *	1995-12-27	1998-07-14	American Home Products Corporation	Water soluble rapamycin esters
US5922730A (en) *	1996-09-09	1999-07-13	American Home Products Corporation	Alkylated rapamycin derivatives
IT1289815B1 (it) *	1996-12-30	1998-10-16	Sorin Biomedica Cardio Spa	Stent per angioplastica e relativo procedimento di produzione
US6015809A (en) *	1998-08-17	2000-01-18	American Home Products Corporation	Photocyclized rapamycin
US6331547B1 (en)	1999-08-18	2001-12-18	American Home Products Corporation	Water soluble SDZ RAD esters
US20010055593A1 (en) *	2000-03-14	2001-12-27	Joseph Sypek	Use of rapamycin and agents that inhibit B7 activity in immunomodulation
US6670355B2 (en)	2000-06-16	2003-12-30	Wyeth	Method of treating cardiovascular disease
ATE411321T1 (de)	2000-09-19	2008-10-15	Wyeth Corp	Wasserlösliche rapamycin-ester
US6399625B1 (en)	2000-09-27	2002-06-04	Wyeth	1-oxorapamycins
US6440991B1 (en)	2000-10-02	2002-08-27	Wyeth	Ethers of 7-desmethlrapamycin
US6399626B1 (en)	2000-10-02	2002-06-04	Wyeth	Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en)	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) *	2001-04-06	2008-05-01	Wyeth Corp	Antineoplastic combinations
TWI233359B (en) *	2001-04-06	2005-06-01	Wyeth Corp	Pharmaceutical composition for treating neoplasm
ZA200603888B (en) *	2001-06-01	2007-05-30	Wyeth Corp	Antineoplastic combinations
UA77200C2 (en)	2001-08-07	2006-11-15	Wyeth Corp	Antineoplastic combination of cci-779 and bkb-569
EP1419153A1 (en)	2001-08-22	2004-05-19	Wyeth	Rapamycin dialdehydes
DK1419154T3 (da)	2001-08-22	2006-01-09	Wyeth Corp	Rapamycin-29-enoler
AR040693A1 (es)	2002-07-30	2005-04-13	Wyeth Corp	Formulaciones parenterales
AU2003272489B2 (en) *	2002-09-17	2008-11-13	Wyeth	Granulated formulation of the rapamycin ester CCI779
DK1539157T3 (da)	2002-09-18	2013-10-07	Univ Pennsylvania	Fremgangsmåde til hæmning af choroidal neovaskularisering
US20050214292A1 (en) *	2002-10-18	2005-09-29	Wyeth	Compositions and methods for diagnosing and treating autoimmune disease
AR042938A1 (es) *	2003-02-06	2005-07-06	Wyeth Corp	Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) *	2003-03-05	2008-07-25	Уайт	Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
DE602004004520T2 (de) *	2003-04-22	2007-11-08	Wyeth	Antineoplastische zusammensetzungen
KR20060085246A (ko) *	2003-09-18	2006-07-26	마커사이트, 인코포레이티드	경공막 전달
PL1735321T3 (pl) *	2004-04-14	2009-04-30	Wyeth Corp	Proces wytwarzania 42-estrów rapamycyny i 32-estrów FK-506 z kwasem dikarboksylowym, prekursory koniugatów rapamycyny oraz przeciwciała
WO2006115509A2 (en)	2004-06-24	2006-11-02	Novartis Vaccines And Diagnostics Inc.	Small molecule immunopotentiators and assays for their detection
US8313763B2 (en) *	2004-10-04	2012-11-20	Tolmar Therapeutics, Inc.	Sustained delivery formulations of rapamycin compounds
MX2007003789A (es) *	2004-10-04	2007-07-20	Qlt Usa Inc	Suministro ocular de formulaciones polimericas para suministro.
DK1848431T3 (da) *	2005-02-09	2016-04-18	Santen Pharmaceutical Co Ltd	Flydende formuleringer til behandling af sygdomme eller tilstande
US8663639B2 (en) *	2005-02-09	2014-03-04	Santen Pharmaceutical Co., Ltd.	Formulations for treating ocular diseases and conditions
WO2006089312A2 (en) *	2005-02-15	2006-08-24	Wyeth	Orally bioavailable cci-779 tablet formulations
WO2007059106A2 (en)	2005-11-14	2007-05-24	Ariad Gene Therapeutics, Inc.	Administration of mntor inhibitor to treat patients with cancer
KR20140093764A (ko)	2006-02-09	2014-07-28	산텐 세이야꾸 가부시키가이샤	안정한 제제와 그 제조 및 사용 방법
ES2563288T3 (es) *	2006-03-23	2016-03-14	Santen Pharmaceutical Co., Ltd	Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
WO2008022256A2 (en) *	2006-08-16	2008-02-21	Blagosklonny Mikhail V	Methods and compositions for preventing or treating age-related diseases
AU2007287809A1 (en) *	2006-08-22	2008-02-28	Novartis Ag	Rapamycin and its derivatives for the treatment of liver-associated fibrosing disorders
EP2083834B1 (en)	2006-09-13	2017-06-21	Elixir Medical Corporation	Macrocyclic lactone compounds and methods for their use
US20080265343A1 (en) *	2007-04-26	2008-10-30	International Business Machines Corporation	Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20100086579A1 (en) *	2008-10-03	2010-04-08	Elixir Medical Corporation	Macrocyclic lactone compounds and methods for their use
ES2645692T3 (es)	2008-11-11	2017-12-07	The Board Of Regents,The University Of Texas System	Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
BRPI1010655A2 (pt) *	2009-04-10	2019-09-03	Qi Haiyan	novos agentes antienvelhecimento e métodos para identificá-los
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
WO2014059295A1 (en)	2012-10-12	2014-04-17	The Board Of Regents Of The University Of Texas System	Use of mtor inhibitors to treat vascular cognitive impairment
WO2014160328A1 (en)	2013-03-13	2014-10-02	The Board Of Regents Of The University Of Texas System	Mtor inhibitors for prevention of intestinal polyp growth
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
EP3089737B1 (en)	2013-12-31	2021-11-03	Rapamycin Holdings, LLC	Oral rapamycin nanoparticle preparations and use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en) *	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US5100899A (en) *	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JPH04230389A (ja) *	1990-07-16	1992-08-19	American Home Prod Corp	ラパマイシン誘導体

1991
- 1991-02-22 US US07/660,470 patent/US5078999A/en not_active Expired - Lifetime
1992
- 1992-02-10 IL IL10090492A patent/IL100904A/en not_active IP Right Cessation
- 1992-02-19 ZA ZA921210A patent/ZA921210B/xx unknown
- 1992-02-20 PT PT100145A patent/PT100145B/pt not_active IP Right Cessation
- 1992-02-20 NZ NZ241671A patent/NZ241671A/en not_active IP Right Cessation
- 1992-02-21 AT AT92907399T patent/ATE202938T1/de not_active IP Right Cessation
- 1992-02-21 IE IE055692A patent/IE920556A1/en not_active IP Right Cessation
- 1992-02-21 DK DK92907399T patent/DK0572542T3/da active
- 1992-02-21 KR KR1019930702484A patent/KR100201517B1/ko not_active Expired - Fee Related
- 1992-02-21 EP EP92907399A patent/EP0572542B9/en not_active Expired - Lifetime
- 1992-02-21 HU HU9302383A patent/HUT70489A/hu unknown
- 1992-02-21 WO PCT/US1992/001399 patent/WO1992014477A1/en not_active Ceased
- 1992-02-21 CA CA002103568A patent/CA2103568A1/en not_active Abandoned
- 1992-02-21 MX MX9200727A patent/MX9200727A/es unknown
- 1992-02-21 SG SG1996004022A patent/SG52404A1/en unknown
- 1992-02-21 DE DE69231927T patent/DE69231927T2/de not_active Expired - Fee Related
- 1992-02-21 ES ES92907399T patent/ES2157901T3/es not_active Expired - Lifetime
- 1992-02-21 AU AU14691/92A patent/AU664545B2/en not_active Ceased
2001
- 2001-08-30 GR GR20010401336T patent/GR3036477T3/el not_active IP Right Cessation
2002
- 2002-12-30 CY CY0200070A patent/CY2305B1/xx unknown

Also Published As

Publication number	Publication date
KR100201517B1 (ko)	1999-06-15
CY2305B1 (en)	2003-07-04
SG52404A1 (en)	1998-09-28
ATE202938T1 (de)	2001-07-15
GR3036477T3 (en)	2001-11-30
IE920556A1 (en)	1992-08-26
ES2157901T3 (es)	2001-09-01
IL100904A0 (en)	1992-11-15
WO1992014477A1 (en)	1992-09-03
EP0572542A4 (en)	1994-06-01
EP0572542A1 (en)	1993-12-08
EP0572542B9 (en)	2001-11-21
MX9200727A (es)	1992-09-01
EP0572542B1 (en)	2001-07-11
DK0572542T3 (da)	2001-09-17
HUT70489A (en)	1995-10-30
NZ241671A (en)	1997-06-24
PT100145A (pt)	1993-08-31
HK1011281A1 (en)	1999-07-09
DE69231927T2 (de)	2001-11-22
PT100145B (pt)	1999-06-30
ZA921210B (en)	1993-08-19
US5078999A (en)	1992-01-07
AU1469192A (en)	1992-09-15
DE69231927D1 (de)	2001-08-16
KR930703001A (ko)	1993-11-29
AU664545B2 (en)	1995-11-23
CA2103568A1 (en)	1992-08-23

Legal Events

Date	Code	Title
1996-03-31	FF	Patent granted
1998-08-16	KB	Patent renewed
2002-09-12	HCA	Change of name of proprietor(s) after amalgamation
2006-10-30	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
EP0572542B1 (en)	2001-07-11	Method of treating systemic lupus erythematosus
IE83403B1 (en)		Method for treating systemic lupus erythematosus
Benito et al.	2001	Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease1
Hollenbach et al.	2004	Inhibition of p38 MAP kinase‐and RICK/NF‐κB‐signaling suppresses inflammatory bowel disease
Wofsy et al.	1981	Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene.
Tervaert et al.	1990	Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre
CA2103571C (en)	2003-04-29	Method of treating pulmonary inflammation
US5679709A (en)	1997-10-21	Medicaments to combat autoimmune diseases
IE61232B1 (en)	1994-10-19	Medicaments to combat chronic graft-versus-host diseases and to combat autoimmune diseases, in particular systemic lupus erythematosus
US20250248991A1 (en)	2025-08-07	Methods for treating neutropenia
Müller	2017	Neuroprogression in schizophrenia and psychotic disorders: the possible role of inflammation
WO1999062525A1 (en)	1999-12-09	Compositions comprising methotrexate and pentostatin for treating rheumatoid arthritis
Casolaro et al.	1993	In vivo characterization of the anti-inflammatory effect of cyclosporin A on human basophils.
EP0744949A1 (en)	1996-12-04	Treatment and/or prevention of type i diabetes mellitus with gamma interferon administration
Melink et al.	1985	Phase I Evaluation and Pharmacokinetics of Tiazofurin (2-β-d-Ribofuranosylthiazole-4-carboxamide, NSC 286193)
WO2009127048A1 (en)	2009-10-22	Method of treating demyelinating diesase
WO1990004398A1 (en)	1990-05-03	A new pharmaceutical use of fusidic acid and derivatives thereof
EP0772442B1 (en)	2002-05-02	Use of immunosuppressive agents for the treatment of schizophrenia
HK1011281B (en)	2002-03-08	Method of treating systemic lupus erythematosus
KR102893744B1 (ko)	2025-11-28	피리메타민을 유효성분으로 포함하는 류마티스 관절염의 치료 또는 예방용 약학 조성물
Kay	1994	Immunosuppressive agents in chronic severe asthma
Hedges et al.	1990	Ciclosporin‐Dependent, nu‐Independent, Mucosal Interleukin 6 Response to Gram‐Negative Bacteria
Shasha et al.	1991	Effect of converting enzyme inhibitor captopril on T cell functions in essential hypertension
Liu et al.	1993	Treatment of experimental autoimmune dacryoadenitis with cyclosporin A
JP2010111581A (ja)	2010-05-20	ドーパミンｄ２様受容体アゴニストを有効成分とする医薬及びスクリーニング方法